Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to ...

The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

It’s very exciting,” a melanoma expert said of the experimental cancer vaccine announced by pharmaceutical companies Moderna ...

The results, announced this week by Moderna and Merck, could pave the way for a new generation of treatments tailored to ...

Moderna and Merck's personalized mRNA cancer vaccine has achieved the first positive Phase 3 result of its kind.

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Personalized mRNA vaccines are showing promise as a new way to fight cancer, particularly melanoma. The vaccines are designed ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

A mRNA cancer vaccine showed positive results in a late-stage melanoma trial, Moderna and Merck announced Wednesday.